Oragenics Announces U.S. Manufacturing Agreement for ONP-002 Concussion Treatment

Oragenics, Inc. has partnered with Sterling Pharma Solutions for the Good Manufacturing Practice (GMP) production of ONP-002, its lead drug candidate ...
Home/KnloSights/Clinical Trial Updates/Oragenics Announces U.S. Manufacturing Agreement for ONP-002 Concussion Treatment